Search Results

Your search for John Jakob, MD PhD,John Jakob, MD PhD matches 2 pages

Showing 1 - 2

By Ronald Piana / April 10, 2021

Towering Figure in Cancer Drug Development, José Baselga, MD, PhD, FASCO, Dies at Age 61

José Baselga, MD, PhD, FASCO, a global innovator in novel cancer therapeutics, led research efforts in his native country of Spain and in the United States, most notably as Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK). “My moment of recognition as an oncologist came early,...

issues in oncology

By John Jakob, MD PhD / March 15, 2014

After Next-Generation Sequencing: Guiding Patients to the Right Treatment

In the near future, community oncologists will be tasked with helping patients interpret the results of next-generation sequencing of their tumors. Specifically, we will help patients choose an academic center with a phase I targeted therapy program that is a plausible fit for their disease....

Nov

Today In Oncology

Search Results

Your search for John Jakob, MD PhD,John Jakob, MD PhD matches 2 pages

Towering Figure in Cancer Drug Development, José Baselga, MD, PhD, FASCO, Dies at Age 61

After Next-Generation Sequencing: Guiding Patients to the Right Treatment

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC